Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting
November 13, 2019 08:00 ET
|
Samumed
Data showed that lorecivivint had a safety profile similar to placebo The Company previously presented data from Phase 2 trials demonstrating sustained pain and function improvements out to 24 and 52...
Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors
October 02, 2019 08:00 ET
|
Samumed
SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression through potent inhibition of CDC-like kinases (CLKs) Publication highlights new discovery of a relationship between Wnt...
Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimer’s Disease
July 18, 2019 08:00 ET
|
Samumed
SAN DIEGO, July 18, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of preclinical data demonstrating that SM07883 inhibits tau pathology and associated neuroinflammation,...
Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis
June 19, 2019 08:00 ET
|
Samumed
SAN DIEGO, June 19, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has dosed the first patient in its Phase 3 STRIDES-X-ray trial of lorecivivint (SM04690), a CLK/DYRK inhibitor that...
Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
May 02, 2019 08:00 ET
|
Samumed
Pivotal STRIDES trials to be conducted to support lorecivivint as a potential disease-modifying treatment for knee osteoarthritis First patient dosing is anticipated in the second quarter of 2019 ...
Samumed Announces Multiple Presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
April 10, 2019 08:00 ET
|
Samumed
SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it presented new clinical data from its phase 2b trial of a novel small-molecule Wnt pathway inhibitor, SM04690,...
Samumed Doses First Subject in Phase 1 Trial of SM07883, a Potential Treatment for Alzheimer’s Disease
April 04, 2019 08:00 ET
|
Samumed
DYRK1A Inhibition as a Potential Treatment for Alzheimer’s Disease Supported by Data Presented at International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2019) SAN DIEGO, April 04,...
Samumed to Present Clinical Data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
March 07, 2019 08:00 ET
|
Samumed
SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that clinical data from its successful phase 2a trial of SM04690 for the treatment of knee osteoarthritis (OA) has been...
Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis
February 28, 2019 08:30 ET
|
Samumed
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding the...
Samumed to Present Novel Biological Targets of SM04690 for Treatment of Knee Osteoarthritis
January 29, 2019 08:00 ET
|
Samumed
Study results highlight novel drug discovery targets for the treatment of knee osteoarthritis Company to present data in late-breaking poster at Orthopaedic Research Society (ORS) 2019 Annual...